Seattle Genetics, Inc. (SGEN) financial statements (2020 and earlier)

Company profile

Business Address 21823 30TH DRIVE SE
BOTHELL, WA 98021
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments811870376418411463448
Cash and cash equivalents275193648478115159
Short-term investments536677312334332348289
Receivables236190182157146153150
Inventory, net of allowances, customer advances and progress billings86927367537571
Inventory86927367537571
Other undisclosed current assets44444037432637
Total current assets:1,1771,196672680654717706
Noncurrent Assets
Operating lease, right-of-use asset656769 
Property, plant and equipment155145131115104101101
Long-term investments and receivables57   492310
Long-term investments57   492310
Intangible assets, net (including goodwill)575575575575575551551
Goodwill275275275275275251251
Intangible assets, net (excluding goodwill)300300300300300300300
Other noncurrent assets177115121164122176213
Other undisclosed noncurrent assets   59   
Total noncurrent assets:1,029901896913850851875
TOTAL ASSETS:2,2062,0981,5681,5931,5031,5681,581
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:259583739191157145
Accounts payable5258373944  
Accrued liabilities207   147  
Other undisclosed accounts payable and accrued liabilities     157145
Deferred revenue 717 
Debt 98    
Contract with customer, liability27343636
Other undisclosed current liabilities 173160142   
Total current liabilities:259246222208225194181
Noncurrent Liabilities
Long-term debt and lease obligation686971    
Operating lease, liability686971 
Liabilities, other than long-term debt3221041018
Contract with customer, liability 615
Other liabilities32210443
Other undisclosed noncurrent liabilities   61   
Total noncurrent liabilities:7072747141018
Total liabilities:330318296279229203198
Stockholders' equity
Stockholders' equity attributable to parent1,8761,7801,2721,3131,2741,3651,382
Common stock0000000
Additional paid in capital3,3593,2882,6882,6512,5982,5692,520
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(1,483)(1,509)(1,417)(1,338)(1,325)(1,205)(1,137)
Total stockholders' equity:1,8761,7801,2721,3131,2741,3651,382
TOTAL LIABILITIES AND EQUITY:2,2062,0981,5681,5931,5031,5681,581

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues290213218195175169170
Cost of revenue14(11)(11)(10)(10)(18)(19)
Gross profit:304202208185164152151
Operating expenses(342)(292)(246)(239)(255)(197)(181)
Operating loss:(38)(90)(39)(54)(90)(46)(30)
Nonoperating income (expense)
(Investment Income, Nonoperating)
4422(60)(22)107
Other undisclosed income from continuing operations before equity method investments, income taxes50   7  
Income (loss) from continuing operations before income taxes:16(86)(37)(51)(143)(67)76
Other undisclosed income from continuing operations    24  
Net income (loss):16(86)(37)(51)(120)(67)76
Other undisclosed net income (loss) attributable to parent10(6)(43)38   
Net income (loss) available to common stockholders, diluted:26(92)(79)(13)(120)(67)76

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):16(86)(37)(51)(120)(67)76
Other comprehensive income (loss)(0)(0)000(0)0
Comprehensive income (loss):15(86)(36)(51)(120)(68)76
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(6)(43)38   
Comprehensive income (loss), net of tax, attributable to parent:26(92)(79)(13)(120)(68)76

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: